Candel Therapeutics (CADL) Other financing activities (2020 - 2025)

Candel Therapeutics (CADL) has 5 years of Other financing activities data on file, last reported at $4000.0 in Q4 2025.

• For the quarter ending Q4 2025, Other financing activities fell 98.92% year-over-year to $4000.0; the trailing twelve-month figure through Dec 2025 stood at $516000.0 (down 69.45% YoY), and the FY2025 full-year result was $516000.0, down 69.45% from the prior year.
• Other financing activities fell to $4000.0 in Q4 2025, from $20000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $71.3 million in Q4 2021 to a low of -$42000.0 in Q2 2021.
• A 4-year average of $5.3 million and a median of $90000.0 in 2021 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities jumped 245762.07% in 2021 and tumbled 99.95% in 2022, its largest moves.
• Tracing CADL's Other financing activities over 4 years: stood at $71.3 million in 2021, then sank by 99.95% to $36000.0 in 2022, then surged by 927.78% to $370000.0 in 2024, then slumped by 98.92% to $4000.0 in 2025.
• Business Quant data shows CADL's Other financing activities at $4000.0 in Q4 2025, $20000.0 in Q3 2025, and $246000.0 in Q2 2025.